Brief: Detalimogene Demonstrates Improved Complete Response Rate Of 62% At 6 Months

enGene Therapeutics

11/11/2025 12:53

Nov 11 (Reuters) - enGene Holdings Inc ENGN.O:

DETALIMOGENE DEMONSTRATES IMPROVED COMPLETE RESPONSE RATE OF 62% AT 6 MONTHS

ENGENE HOLDINGS INC - 42% OF PATIENTS EXPERIENCED TREATMENT-RELATED ADVERSE EVENTS

ENGENE HOLDINGS INC - 1.6% OF PATIENTS HAD DOSE INTERRUPTIONS DUE TO ADVERSE EVENTS

ENGENE HOLDINGS INC: 0.8% OF PATIENTS EXPERIENCED DOSE DISCONTINUATIONS DUE TO TRAES

Source text: ID:nBw7kBBjga

Further company coverage: ENGN.O

 ((reuters.briefs@thomsonreuters.com;))